These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 25759010)

  • 1. Treatment of secondary pulmonary hypertension with bosentan after left ventricular assist device implantation.
    LaRue SJ; Garcia-Cortes R; Nassif ME; Vader JM; Ray S; Ravichandran A; Rasalingham R; Silvestry SC; Ewald GA; Wang IW; Schilling JD
    Cardiovasc Ther; 2015 Apr; 33(2):50-5. PubMed ID: 25759010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation.
    Hefke T; Zittermann A; Fuchs U; Schulte-Eistrup S; Gummert JF; Schulz U
    Thorac Cardiovasc Surg; 2012 Feb; 60(1):26-34. PubMed ID: 21432755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients.
    Mikus E; Stepanenko A; Krabatsch T; Loforte A; Dandel M; Lehmkuhl HB; Hetzer R; Potapov EV
    Eur J Cardiothorac Surg; 2011 Oct; 40(4):971-7. PubMed ID: 21354812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off-label use of pulmonary vasodilators after left ventricular assist device implantation: Calling in the evidence.
    Papathanasiou M; Ruhparwar A; Kamler M; Rassaf T; Luedike P
    Pharmacol Ther; 2020 Oct; 214():107619. PubMed ID: 32599009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.
    Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of treatment with a combination of cardiac rehabilitation and bosentan in patients with pulmonary Langerhans cell histiocytosis associated with pulmonary hypertension.
    Fukuda Y; Miura S; Fujimi K; Yano M; Nishikawa H; Yanagisawa J; Hiratsuka M; Shiraishi T; Iwasaki A; Saku K
    Eur J Prev Cardiol; 2014 Dec; 21(12):1481-3. PubMed ID: 23897898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device.
    Imamura T; Kinugawa K; Hatano M; Kato N; Minatsuki S; Muraoka H; Inaba T; Maki H; Shiga T; Yao A; Kyo S; Ono M; Nagai R
    J Artif Organs; 2013 Mar; 16(1):101-4. PubMed ID: 23015200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes of Patients Treated With Pulmonary Vasodilators Early and in High Dose After Left Ventricular Assist Device Implantation.
    Critoph C; Green G; Hayes H; Baumwol J; Lam K; Larbalestier R; Chih S
    Artif Organs; 2016 Jan; 40(1):106-14. PubMed ID: 25994765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series.
    Mathijssen H; Huitema MP; Bakker ALM; Mager JJ; Snijder RJ; Grutters JC; Post MC
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(1):74-78. PubMed ID: 33093771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of centrifugal left ventricular assist device as a bridge to candidacy in severe heart failure with secondary pulmonary hypertension.
    Kutty RS; Parameshwar J; Lewis C; Catarino PA; Sudarshan CD; Jenkins DP; Dunning JJ; Tsui SS
    Eur J Cardiothorac Surg; 2013 Jun; 43(6):1237-42. PubMed ID: 23345184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension.
    Perez-Villa F; Cuppoletti A; Rossel V; Vallejos I; Roig E
    Clin Transplant; 2006; 20(2):239-44. PubMed ID: 16640533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pulmonary vascular resistance before left ventricular assist device implantation on short- and long-term post-transplant survival.
    Tsukashita M; Takayama H; Takeda K; Han J; Colombo PC; Yuzefpolskaya M; Topkara VK; Garan AR; Mancini DM; Kurlansky PA; Naka Y
    J Thorac Cardiovasc Surg; 2015 Nov; 150(5):1352-60, 1361.e1-2. PubMed ID: 26253875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporary right ventricular support following left ventricle assist device implantation: a comparison of two techniques.
    Noly PE; Kirsch M; Quessard A; Leger P; Pavie A; Amour J; Leprince P
    Interact Cardiovasc Thorac Surg; 2014 Jul; 19(1):49-55. PubMed ID: 24659551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery.
    Hirono K; Yoshimura N; Taguchi M; Watanabe K; Nakamura T; Ichida F; Miyawaki T
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):346-51. PubMed ID: 20434177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute hemodynamic effects of single oral dose of bosentan in patients with pulmonary arterial hypertension related to congenital heart disease.
    Ajami G; Ahmadipour M; Amoozgar H; Bourzoee M; Cheriki S; Shakiba AM; Edraki MR
    Congenit Heart Dis; 2014; 9(4):343-8. PubMed ID: 25247216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bosentan on pulmonary hypertension secondary to systolic heart failure.
    Padeletti M; Caputo M; Zacà V; Tsioulpas C; Bernazzali S; Mondillo S; Maccherini M; Jelic S
    Pharmacology; 2013; 92(5-6):281-5. PubMed ID: 24296902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of pulmonary hypertension with left heart disease: a concise review.
    Desai A; Desouza SA
    Vasc Health Risk Manag; 2017; 13():415-420. PubMed ID: 29158679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of continuous-flow and pulsatile-flow blood pumps on reducing pulmonary artery pressure in patients with fixed pulmonary hypertension.
    Ozturk P; Engin AY; Nalbantgil S; Oguz E; Ayik F; Engin C; Yagdi T; Erkul S; Balcioglu O; Ozbaran M
    Artif Organs; 2013 Sep; 37(9):763-7. PubMed ID: 24033601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan in heart transplantation candidates with severe pulmonary hypertension: efficacy, safety and outcome after transplantation.
    Perez-Villa F; Farrero M; Cardona M; Castel MA; Tatjer I; Penela D; Vallejos I
    Clin Transplant; 2013; 27(1):25-31. PubMed ID: 22861120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.